Table 5.
Influence of risk factors on all-cause mortality and progression into the next more advanced stage (critical [CR]-phase) in COVID-19 patients in the complicated (CO)-phase with procalcitonin levels > 0.5 ng/ml (PCT↑)
| n = 286 | All-cause mortality (death from any cause incl. COVID-19) n = 109 |
Progression into next more advanced stage (CR-phase) n = 83 |
|---|---|---|
| Antibiotic treatment | ||
| Yes (n = 244, 85%) | 98 (40% CI 34.0–46.7) | 70 (29% CI 23.1–34.8) |
| No (n = 42, 15%) | 11 (26% CI 13.9–42.0) | 13 (31% CI 17.6–47.1) |
| p (p-mult) | 0.089 (0.029) | 0.85 (n.s.) |
| Gender | ||
| M (n = 195, 68%) | 75 (38% CI 31.6–46.1) | 67 (34% CI 27.7–41.5) |
| F (n = 91, 32%) | 34 (37% CI 27.4–48.1) | 16 (18% CI 10.4–27.0) |
| p (p-mult) | 0.90 (n.s.) | 0.0034 (0.0034) |
| Age | ||
| 18–55 (n = 50, 17%) | 7 (14% CI 5.8–26.7) | 17 (34% CI 21.2–48.8) |
| 56–75 (n = 104, 36%) | 26 (25% CI 17.0–34.4) | 35 (34% CI 24.7–43.6) |
| > 75 (n = 132, 46%) | 76 (58% CI 48.7–66.1) | 31 (23% CI 16.5–31.6) |
| p (p-mult) | < 0.001 (< 0.001) | 0.16 (n.s.) |
| Charlson Comorbidity Score | ||
| 0–2 (n = 166, 58%) | 49 (30% CI 22.7–37.1) | 55 (33% CI 26.0–40.8) |
| 3–4 (n = 65, 23%) | 31 (48% CI 35.1–60.5) | 14 (22% CI 12.3–33.5) |
| > 4 (n = 55, 19%) | 29 (53% CI 38.8–66.3) | 14 (25% CI 14.7–39.0) |
| p (p-mult) | 0.0017 (n.s.) | 0.19 (n.s.) |
m male, f female, age given in years, p value p value of the univariate analysis, p-mult p value for the multivariate logistic regression analysis with the multiple influence variables antibiotics, gender, age, CCI (after backward selection for p > 0.05), n.s. not significant in the multivariate analysis, CI 95% confidence interval